Article
Oncology
Kathryn M. LaPorte, Rosmely Hernandez, Alicia Santos Savio, Thomas R. Malek
Summary: Researchers tested an IL-2 biologic, mIL-2/CD25, which preferentially stimulates the high-affinity IL-2R, and found that it can effectively support antitumor responses to immunogenic tumors as a monotherapy or in combination with a PD-1 checkpoint blockade. This treatment increases the frequency and function of tumor-specific CD8(+) T effector cells and induces long-term antitumor memory responses in the tumor microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jianjun Hu, Jiangyi He, Yunlong Wang, Yang Zhao, Kejing Fang, Yan Dong, Yanrong Chen, Yue Zhang, Chi Zhang, Hongwei Wang, Jun Tan, Junyi Wang, Ruiyang Zi, Chengxiang Liu, Houjie Liang, Yanli Guo, Juanjuan Ou
Summary: By using ultrasound-stimulated nanobubbles (USNB) to enhance tumor immunogenicity, the efficacy of anti-programmed cell death protein 1 (anti-PD1) immune checkpoint blockade (ICB) can be improved. USNB promotes the infiltration and antitumor activity of CD8+ T cells, and the combination of USNB and anti-PD1 blockade enhances systemic antitumor immunity and generates long-term immune memory protection after complete tumor remission.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Alexander A. Pieper, Luke M. Zangl, Dan V. Speigelman, Arika S. Feils, Anna Hoefges, Justin C. Jagodinsky, Mildred A. Felder, Noah W. Tsarovsky, Ian S. Arthur, Ryan J. Brown, Jen Birstler, Trang Le, Peter M. Carlson, Amber M. Bates, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Amy K. Erbe, Paul M. Sondel, Ravi B. Patel, Zachary S. Morris
Summary: Combining CpG+OX40 in situ vaccine with radiation therapy significantly enhances the anti-tumor response in immunologically cold tumor models, where CpG+OX40 alone is not effective. Radiation therapy prior to CpG+OX40 improves the local tumor response and survival in these models.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Thuy T. Tran, Jasmine Caulfield, Lin Zhang, David Schoenfeld, Dijana Djureinovic, Veronica L. Chiang, Victor Oria, Sarah A. Weiss, Kelly Olino, Lucia B. Jilaveanu, Harriet M. Kluger
Summary: Targeting tumor-associated blood vessels for immune infiltration enhancement has the potential to improve treatment effectiveness, but there is limited data on the effects of anti-angiogenesis on the tumor microenvironment. This study evaluated the combination of anti-PD-1 therapy with either anti-VEGF or lenvatinib in melanoma models and found that both combinations improved survival and decreased tumor growth. The effects on the tumor microenvironment, such as cytokine signaling and immune cell populations, differed between the two combinations. These findings provide valuable insights into the dual targeting of PD-1 and angiogenesis for melanoma treatment.
Article
Immunology
Merve Uslu, Esra Albayrak, Fatih Kocabas
Summary: This study found that IL-2 and its receptor play a crucial role in immune response regulation. The small molecule Ro 26-4550 trifluoroacetate is able to competitively inhibit the interaction between IL-2 and its receptor, promoting the expansion and self-renewal ability of hematopoietic stem cells. Furthermore, Ro treatment induces an increase in CD25 expressing cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Immunology
Yifang Shui, Xin Hu, Hiroshi Hirano, Kisato Kusano, Hirotake Tsukamoto, Mengquan Li, Kenichiro Hasumi, Wen-Zhi Guo, Xiao-Kang Li
Summary: Dendritic cells play a crucial role in the immune response against tumors, but can be influenced by an immunosuppressive environment. Aureobasidium pullulan-derived beta-glucan has shown potential in enhancing the anti-tumoral activity of dendritic cells and inhibiting tumor growth.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Immunology
Min Gu, Yuexinzi Jin, Xun Gao, Wenying Xia, Ting Xu, Shiyang Pan
Summary: IL-37 is a newly discovered cytokine that has the ability to suppress inflammation and tumor growth. It exerts its effects by inhibiting the production and functions of proinflammatory cytokines and regulating the immune system. Recent studies suggest that IL-37 may be a therapeutic target for cancer monitoring.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Rilan Bai, Jiuwei Cui
Summary: Cancer cells adapt to increasing energy and biosynthetic demands by reprogramming their metabolic pathways via mitochondria, which play crucial roles in the survival, immune evasion, tumor progression, and treatment resistance of the hypoxic tumor microenvironment. Targeting the mitochondria-related pathway with anticancer drugs can enhance the immune recognition of cancer cells, tumor antigen presentation ability, and anti-tumor function of immune cells. This review focuses on the effects of mitochondrial morphology and function on immune cells, the impact of mitochondrial changes on tumor immune escape and immune cell function, and the research progress and challenges of novel anti-tumor immunotherapy strategies targeting mitochondria.
Article
Oncology
Elizabeth R. Sturgill, Annah S. Rolig, Stefanie N. Linch, Courtney Mick, Melissa J. Kasiewicz, Zhaoyu Sun, Peter G. Traber, Harold Shlevin, William L. Redmond
Summary: Combining Gal-3 inhibition with aOX40 therapy promotes tumor regression and increases survival by reducing M-MDSC-mediated immune suppression, enhancing CD8(+) T cell recruitment, leading to improved tumor regression and survival.
Article
Immunology
Yangyihua Zhou, Guiqi Quan, Yujun Liu, Ning Shi, Yahui Wu, Qiuju Liu, Xiang Gao, Ran Zhang, Longlong Luo
Summary: An antibody-fusion protein drug, IMAB362-mIL-21, has been developed to achieve tumor targeting and activate local anti-tumor immune response more effectively. It shows stronger anti-tumor effects without obvious hematological toxicity, suggesting better application prospects than single drugs or their combination.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Immunology
Yang Li, Gen Li, Jian Zhang, Xiaoli Wu, Xi Chen
Summary: Gamma delta T cells, a unique subgroup of T cells, can promote anti-tumor immune response but also potentially contribute to tumor progression. Studies have summarized and discussed their functions and effects in cancer, as well as reviewed recent anti-tumor immunotherapy based on gamma delta T cells, and identified existing problems and future prospects of this immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Xiaoming Zhou, Chengxiao Fu, Xisha Chen
Summary: With the increasing understanding of the relationship between tumor cells and the tumor immune microenvironment, immunotherapy based on immune checkpoint blockade has made significant progress in recent years. However, resistance to immunotherapy has limited its efficacy, with an overall response rate of only 20% to 40%. Therefore, further research on the regulation of the tumor microenvironment and antitumor immunity is urgently needed.
Article
Oncology
Arthur Battistoni, Louis Lantier, Anne di Tommaso, Celine Ducournau, Laurie Lajoie, Mahtab Samimi, Lois Coenon, Clement Riviere, Mathieu Epardaud, Leslie Hertereau, Agathe Poupee-Beauge, Juliette Rieu, Marie-Noelle Mevelec, Gordon Scott Lee, Nathalie Moire, Stephanie Germon, Isabelle Dimier-Poisson
Summary: Intranasal administration of immunotherapeutic agents shows promise in targeting lung metastases and reducing cancer mortality.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Wan Xing Hong, Idit Sagiv-Barfi, Debra K. Czerwinski, Adrienne Sallets, Ronald Levy
Summary: The combination of synthetic TLR9 ligand CpG and agnostic OX40 antibody can trigger systemic antitumor immune responses, eradicating metastatic disease. Applying this in situ immunotherapy in the neoadjuvant setting can improve survival and minimize adverse effects.
Article
Chemistry, Multidisciplinary
Yuexia Xie, Huishan Li, Lei Xu, Hanbing Zou, Xingang Wang, Xiaozhen He, Qianyun Tang, Yan Zhou, Xue Zhao, Xiaojing Chen, Hongmei Liu, Jun Pu, Dan Luo, Peifeng Liu
Summary: Immunotherapy combined with radiotherapy shows potential in enhancing cancer treatment by generating a powerful abscopal effect. However, immune tolerance mechanisms in the tumor microenvironment can hinder this effect. In this study, a DNA nanocluster (DNAnc) was designed to carry CpG ODNs and repolarize macrophages, resulting in a robust abscopal effect. Mechanistic studies revealed that DNAncs were endocytosed by macrophages in the cancer tissue and induced the accumulation of repolarized macrophages, leading to potent and durable antitumor immunity, which provides a novel strategy for cancer immunotherapy enhancement.
ADVANCED MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Anna S. Warden, Todd A. Triplett, Aram Lyu, Emily K. Grantham, Moatasem M. Azzam, Adriana DaCosta, Sonia Mason, Yuri A. Blednov, Lauren Ir Ehrlich, R. Dayne Mayfield, R. Adron Harris
Summary: The depletion of microglia does not affect the sedative or hypnotic effects of acute intoxication, nor does it change the escalation or maintenance of chronic voluntary alcohol consumption, indicating that microglia are not the primary effector cell responsible for regulating alcohol behaviors. Instead, the upregulation of alcohol-responsive, reactive astrocyte genes suggests that astrocytes may play a role in regulating these alcohol behaviors. Activation of microglia through repeated immune stimulation blocks escalations in alcohol intake, indicating that microglia regulate drinking behaviors with sufficient immune activation. This study provides insight into the causal and consequential roles of microglia in the transition from alcohol use to dependence.
Review
Oncology
Michael W. Lee, Mihailo Miljanic, Todd Triplett, Craig Ramirez, Kyaw L. Aung, S. Gail Eckhardt, Anna Capasso
Summary: Recent advancements in pre-clinical screening tools have led to a new era in drug development, with more accurate prediction of clinical effects and adverse events for candidate therapeutic agents. However, careful evaluation is necessary to determine the individual merits of these translational research tools to provide appropriate information for clinical researchers to conduct pre-clinical screening in an accelerated and rational manner.
CANCER AND METASTASIS REVIEWS
(2021)
Article
Multidisciplinary Sciences
Zhaoyu Sun, Richard Nyberg, Yaping Wu, Brady Bernard, William L. Redmond
Summary: The TSA Opal multiplex immunohistochemistry protocol has been used to characterize immune infiltration in human cancers. Two improved protocols were developed for a 7-color panel with 6 biomarkers, showing that antigen retrieval method is crucial for staining intensity. The study demonstrated the importance of proper antigen retrieval method in multiplex immunohistochemistry and its impact on individual biomarker staining intensity.
Article
Oncology
Dana A. Emerson, Annah S. Rolig, William L. Redmond
Summary: The combination of CTLA-4 blockade and OX40-specific monoclonal antibody has been shown to enhance antitumor immunity by upregulating Eomes expression in CD8(+) T cells. Further modulation of Eomes expression through ITK signaling with ibrutinib can lead to enhanced tumor regression and improved survival, making the combination therapy a potential triple therapy option for improving immunotherapy efficacy.
CANCER IMMUNOLOGY RESEARCH
(2021)
Meeting Abstract
Oncology
Jodi A. Kagihara, Bradley Corr, Jose Maria Pacheco, S. Lindsey Davis, Christopher Hanyoung Lieu, Sunnie S. Kim, Antonio Jimeno, Amy M. Heim, John A. DeMattei, Gilad Gordon, Todd A. Triplett, S. Gail Eckhardt, James D. Winkler, Anthony D. Piscopio, Jennifer Robinson Diamond
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan D. Curti, Walter J. Urba, Brian D. Piening, William L. Redmond
Summary: Trough levels of ipilimumab may be a useful biomarker for long-term survival of patients with advanced melanoma, with associations with CXCL11 and sCD25 suggesting a baseline-driven E-R relationship, while associations with CRP and IL-6 levels indicate response-driven E-R relationship.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Brie Chun, Joanna Pucilowska, ShuChing Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A. Fields, Valerie Conrad, Mark Schmidt, Walter J. Urba, Alison K. Conlin, Heather L. McArthur, David B. Page
Summary: This study investigates the effects of pembrolizumab combined with paclitaxel or capecitabine on T-cell subsets in triple-negative breast cancer patients. The results show that these treatments result in similar lymphodepletions across peripheral T-cell subsets and do not alter T-cell clonal diversity. The findings contribute to our understanding of the impact of chemoimmunotherapy on the immune system.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Rashi Yadav, William L. Redmond
Summary: This review discusses the impact of OX40 agonists on T cell function and the therapeutic potential of OX40 agonists alone or in conjunction with ICB for patients with advanced malignancies.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Oncology
Annah S. Rolig, Daniel C. Rose, Grace Helen McGee, Werner Rubas, Saul Kivimae, William L. Redmond
Summary: This study aims to evaluate whether intratumoral NKTR-262 combined with systemic BEMPEG treatment can improve tumor-specific immunity and survival. The results showed that BEMPEG+NKTR-262 significantly improved survival and inhibited tumor growth by expanding activated CD8(+) T cells and enhancing cytolytic function.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Yoshinobu Koguchi, William L. Redmond
Summary: While immune checkpoint blockade has revolutionized cancer treatment, the majority of patients do not benefit from it. Various efforts have been made to interrogate the immune system using different biospecimens, technologies, and disciplines, but consistent biomarkers of response have remained elusive. Pharmacokinetics studies, however, provide critical information and may reveal useful biomarkers.
IMMUNOLOGICAL INVESTIGATIONS
(2022)
Article
Oncology
Milad Soleimani, Alexander Somma, Tamer Kaoud, Ria Goyal, Jorge Bustamante, Dennis C. Wylie, Nisha Holay, Agnieszka Looney, Uma Giri, Todd Triplett, Kevin Dalby, Jeanne Kowalski, S. Gail Eckhardt, Carla Van Den Berg
Summary: JNK-IN-8, a covalent JNK inhibitor, suppresses the growth of triple-negative breast cancer (TNBC) by activating TFEB/TFE3 and inducing lysosome biogenesis and autophagy via mTOR inhibition independently of JNK.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Clinical Neurology
Sam A. Bazzi, Cole Maguire, Nisha Holay, Janelle Geltman, Kerin Hurley, Chris DiPasquale, Melissa Abigania, Eric Olson, Lauren I. R. Ehrlich, Todd A. Triplett, Esther Melamed
Summary: The study found that COVID-19 B cell depleted patients can still generate and sustain cellular and humoral immune responses for up to 12 months, with specific T and B cell signatures that could be used as clinical biomarkers.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Biochemical Research Methods
Daniel C. Rose, Annah S. Rolig, William L. Redmond
Summary: This article describes a flow cytometry panel specifically designed to assess the expression of activation and exhaustion markers in expanding lymphocyte populations in tumor-bearing mice. It enables the assessment of multiple functional states and immune checkpoint markers across various immune cell subsets in murine whole blood, lymph nodes, and tumor.
Meeting Abstract
Immunology
Todd A. Triplett, Joshua Rios, Srividya Kottapalli, Andrew D. Weinberg, Alexander Somma, Trevor Sandoval
JOURNAL OF IMMUNOLOGY
(2021)
Article
Oncology
Elizabeth R. Sturgill, Annah S. Rolig, Stefanie N. Linch, Courtney Mick, Melissa J. Kasiewicz, Zhaoyu Sun, Peter G. Traber, Harold Shlevin, William L. Redmond
Summary: Combining Gal-3 inhibition with aOX40 therapy promotes tumor regression and increases survival by reducing M-MDSC-mediated immune suppression, enhancing CD8(+) T cell recruitment, leading to improved tumor regression and survival.